



Xtampza[®] ER (oxycodone) – Label updates

- On November 7, 2017, [Collegium Pharmaceuticals announced](#) the FDA approval of updates to the [Xtampza ER \(oxycodone\)](#) drug label regarding data from pharmacokinetic and human abuse potential studies, along with support from *in vitro* data, indicating that Xtampza ER has physicochemical properties that are expected to reduce abuse via the oral and intranasal routes.
 - However, abuse of Xtampza ER by injection and by the oral and nasal routes of administration is still possible.
- Xtampza ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
- Xtampza ER carries a boxed warning for addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction; and risks from concomitant use with benzodiazepines or other CNS depressants.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.